Loading
HJB647 low dose / Heart Failure With Reduced Ejection Fraction / HJB647 high dose · Phase 1 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 trial registration for HJB647, a novel therapeutic under investigation in heart failure with reduced ejection fraction. The study is currently recruiting and has not yet reported results; it is designed to evaluate safety, tolerability, and pharmacokinetics at two doses versus placebo over 33 days.
Phase 1, Interventional, Randomized, Crossover, Double masking, Treatment purpose. Heart Failure With Reduced Ejection Fraction; age from 18 Years; to 100 Years. Intervention: HJB647 low dose; HJB647 high dose. Compared with: Placebo — Placebo Comparator. n = 12. 6 sites: United States, Canada.
This is a Phase 1 trial registration for HJB647, a novel therapeutic under investigation in heart failure with reduced ejection fraction. The study is currently recruiting and has not yet reported results; it is designed to evaluate safety, tolerability, and pharmacokinetics at two doses versus placebo over 33 days.
This is a registry record with no results posted; no safety or tolerability data are reported. Very small planned sample size (12) limits generalizability of safety findings.
No clinical impact can be assessed until results are posted. This preliminary Phase 1 safety data will inform whether HJB647 warrants advancement to Phase 2 efficacy trials.
Phase 1 safety and tolerability study with planned enrollment of 12 participants; no results posted in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed until results are posted. This preliminary Phase 1 safety data will inform whether HJB647 warrants advancement to Phase 2 efficacy trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07465653). This is a study registration, not published results. Lead sponsor: Novartis Pharmaceuticals. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 12 participants (ESTIMATED). Conditions: Heart Failure With Reduced Ejection Fraction. Interventions: DRUG: HJB647 low dose; DRUG: HJB647 high dose; OTHER: Placebo. Primary outcome measures: Number of participants with Adverse Events (AEs) , Up to 33 days; Number of participants with clinically significant changes in vital signs , Up to 33 days. Brief summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.